Solid Biosciences shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $8 to $20.
Portfolio Pulse from Benzinga Newsdesk
Solid Biosciences' stock (SLDB) experienced a price increase following an upgrade by Piper Sandler from Neutral to Overweight, along with a price target raise from $8 to $20.
March 14, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Solid Biosciences' stock price is likely to experience short-term growth following the upgrade by Piper Sandler from Neutral to Overweight and the significant increase in its price target from $8 to $20.
Stock upgrades by reputable financial institutions like Piper Sandler often lead to increased investor confidence and demand, driving up the stock price. The substantial raise in the price target from $8 to $20 further underscores the firm's positive outlook on SLDB, likely influencing investor sentiment and stock performance positively in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100